Skip to content

13F-HR filed by Cormorant Asset Management, LP

Cormorant Asset Management, LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 35 holding rows worth $2,162,580,277.

Accession
0001583977-26-000001
Filed
2026-02-17
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2025

A holdings report, 35 entries on the cover page, a total value of $2,162,580,277 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,162,580,277 with VALUE read as dollars as filed, 13F file number 028-15949. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
PRAXIS PRECISION MEDICINES I74006W207COM NEW950,000$280,003,000dollars as filed
BRIDGEBIO ONCOLOGY THERAPEUT107924102COM NEW17,878,594$223,839,997dollars as filed
ABIVAX SA-00370M103SPONSORED ADS1,350,000$182,054,250dollars as filed
INVESCO QQQ TR46090E103COM250,000$153,577,500dollars as filedput
EYEPOINT INC COM NEW30233G209Stock8,265,000$151,001,550dollars as filed
iShares Russell 2000 ETF464287655SHS500,000$123,080,000dollars as filedput
SPDR SER TR78464A870S&P BIOTECH1,000,000$121,930,000dollars as filedput
RAPPORT THERAPEUTICS INC COM75383L102Stock3,027,521$91,854,987dollars as filed
BRIDGEBIO PHARMA INC10806X102COM1,200,000$91,788,000dollars as filed
BRIGHT MINDS BIOSCIENCES INC10919W405COMMON STOCK1,059,331$82,670,191dollars as filed
EDGEWISE THERAPEUTICS INC28036F105COM3,285,000$81,517,275dollars as filed
OLEMA PHARMACEUTICALS INC68062P106COM2,750,000$68,750,000dollars as filed
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock4,355,433$57,404,607dollars as filed
INSMED INC COM PAR $.01457669307Stock275,000$47,861,000dollars as filed
ENGENE HOLDINGS INC29286M105COM4,000,000$36,120,000dollars as filed
ALUMIS INC022307102COM3,635,596$35,483,417dollars as filed
MBX BIOSCIENCES INC COM55287L101Stock1,120,000$35,324,800dollars as filed
NEWAMSTERDAM PHARMA CO NVN62509109COMMON STOCK1,000,000$35,080,000dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS1,325,000$33,138,250dollars as filed
PHARVARIS NVN69605108COMMON STOCK1,083,000$30,053,250dollars as filed
BIOAGE LABS INC COM09077V100Stock2,040,605$26,997,204dollars as filed
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR100,000$21,324,000dollars as filed
TARSUS PHARMACEUTICALS INC87650L103COMMON STOCK250,000$20,470,000dollars as filed
CORBUS PHARMACEUTICALS21833P301COM NEW2,344,971$19,088,064dollars as filed
GH RESEARCH PLC ORDINARY SHARESG3855L106Stock1,300,000$16,510,000dollars as filed
ORUKA THERAPEUTICS INC COM687604108Stock533,340$16,165,535dollars as filed
ARCUTIS BIOTHERAPEUTICS INC03969K108COM500,000$14,520,000dollars as filed
CRINETICS PHARMACEUTICALS INC COM22663K107Stock300,000$13,965,000dollars as filed
AXSOME THERAPEUTICS INC. COM05464T104Stock75,000$13,698,000dollars as filed
CABALETTA BIO INC12674W109COMMON STOCK4,400,000$9,636,000dollars as filed
JANUX THERAPEUTICS INC47103J105COM650,000$8,970,000dollars as filed
COGENT BIOSCIENCES INC19240Q201COM225,000$7,992,000dollars as filed
VAXCYTE INC COM92243G108Stock125,000$5,767,500dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM400,000$4,832,000dollars as filed
BIOHAVEN LTDG1110E107COM10,000$112,900dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001583977-26-000001this filing2026-02-17acceptance time not in the bulk data set